NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD

Countries: Kazakhstan

Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Age ≥18 years at the time of inclusion;

* Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort;
* Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits
* Laboratory markers of CKD (eGFR \<60 mL/min/1.73 m2 and/or albuminuria/proteinuria\*) measured during the period ≤12 months prior to inclusion in the study and persisting ≥3 months between two measurements without a recorded diagnosis of CKD in the primary medical record prior to inclusion;

  \* any of the following: urine albumin/creatinine ratio (UACR) ≥30 mg/g (3 mg/mmol), Urine protein-creatinine ratio (uPCR) ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or Urine protein-creatinine ratio (uPCR) ≥0.15 mg/d.
* Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study

Exclusion Criteria:

* Absence of a signed ICF in patients in the prospective follow-up group

  * Participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study
  * An established diagnosis of type 1 or type 2 diabetes mellitus.
  * Diagnosis of symptomatic chronic heart failure (CHF), NYHA functional class III-IV, documented in the patient's medical records
  * Diagnosis of AH of secondary genesis

Locations (28)

Temirlanovka, Turkistan Oblast, Kazakhstan
Aktobe, Kazakhstan
Almaty, Kazakhstan
Almaty, Kazakhstan
Almaty, Kazakhstan
Almaty, Kazakhstan
Almaty, Kazakhstan
Almaty, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Astana, Kazakhstan
Esik, Kazakhstan
Karaganda, Kazakhstan
Karaganda, Kazakhstan
Kostanay, Kazakhstan
Semey, Kazakhstan
Shymkent, Kazakhstan
Shymkent, Kazakhstan
Stepnogorsk, Kazakhstan
Turkestan, Kazakhstan
Uzynaghash, Kazakhstan